Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke.
John-Ih LeeMichael GliemGebke GerdesBernd TurowskiMarius KaschnerBastian KrausHans-Peter HartungSebastian JanderPublished in: PloS one (2017)
In our retrospective study acute stenting with subsequent gpIIb/IIIa inhibition was not associated with an increased risk of ICH or in-hospital death.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- liver failure
- healthcare
- atrial fibrillation
- public health
- emergency department
- respiratory failure
- coronary artery disease
- drug induced
- aortic dissection
- acute care
- adverse drug
- intensive care unit
- hepatitis b virus
- cerebral ischemia
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome